SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Merrimack Pharmaceuticals Inc. to Present Phase I Data on MM-302 and Preclinical Data on Companion Diagnostics Both for the Treatment of HER2-Positive Breast Cancer